이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Therma Bright 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rob Fia

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	8.3yrs
CEO 소유권	7.3%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.6yrs

최근 관리 업데이트

Recent updates

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Nov 02

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Jul 04

CEO 보상 분석

Rob Fia 의 보수는 Therma Bright 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Apr 30 2024	n/a	n/a	-CA$3m
Jan 31 2024	n/a	n/a	-CA$3m
Oct 31 2023	n/a	n/a	-CA$3m
Jul 31 2023	n/a	n/a	-CA$4m
Apr 30 2023	n/a	n/a	-CA$3m
Jan 31 2023	n/a	n/a	-CA$3m
Oct 31 2022	n/a	n/a	-CA$4m
Jul 31 2022	CA$733k	CA$125k	-CA$6m
Apr 30 2022	n/a	n/a	-CA$6m
Jan 31 2022	n/a	n/a	-CA$7m
Oct 31 2021	n/a	n/a	-CA$8m
Jul 31 2021	CA$600k	CA$125k	-CA$9m
Apr 30 2021	n/a	n/a	-CA$8m
Jan 31 2021	n/a	n/a	-CA$6m
Oct 31 2020	n/a	n/a	-CA$4m
Jul 31 2020	CA$53k	CA$53k	-CA$627k
Apr 30 2020	n/a	n/a	CA$158k
Jan 31 2020	n/a	n/a	CA$10k
Oct 31 2019	n/a	n/a	-CA$260k
Jul 31 2019	CA$15k	CA$15k	-CA$422k
Apr 30 2019	n/a	n/a	-CA$1m
Jan 31 2019	n/a	n/a	-CA$1m
Oct 31 2018	n/a	n/a	-CA$1m
Jul 31 2018	CA$30k	CA$30k	-CA$1m

보상 대 시장: Canadian 시장에서 비슷한 규모의 회사에 비해 Rob 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: 회사가 수익성이 없는 동안 Rob 의 보상이 증가했습니다.

CEO

Rob Fia (54 yo)

8.3yrs

테뉴어

CA$732,500

보상

Mr. Roberto Fia, also known as Rob, CFA, serves as the Chairman and President of Therma Bright Inc. (formerly known as The Jenex Corporation) and has been its Chief Executive Officer since May 18, 2016. Mr...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Roberto Fia	Chairman	15yrs	CA$732.50k	7.32% CA$ 1.9m
Bruno Maruzzo	Member of Advisory Board	6.3yrs	데이터 없음	데이터 없음
Gilbert Sharpe	Member of Advisory Board	6.5yrs	데이터 없음	데이터 없음
Andrew Peterson	Independent Director	6.7yrs	데이터 없음	0.27% CA$ 71.4k
Douglas Sommerville	Member of Advisory Board	no data	데이터 없음	데이터 없음
Sungbum Huh	Independent Director	6.3yrs	데이터 없음	데이터 없음
Joseph Heng	Independent Director	8.3yrs	데이터 없음	데이터 없음
Stephen McNeill	Member of Advisory Board	6.7yrs	데이터 없음	데이터 없음
Leonidas Notidis	Member of Advisory Board	6.7yrs	데이터 없음	데이터 없음
Michael Bosman	Member of Advisory Board	6.7yrs	데이터 없음	데이터 없음
Steven Bennett	Member of Advisory Board	6.3yrs	데이터 없음	데이터 없음
Too Min	Member of Advisory Board	6yrs	데이터 없음	데이터 없음

6.6yrs

평균 재임 기간

72yo

평균 연령

경험이 풍부한 이사회: THRM 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

Therma Bright 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Therma Bright Inc. Appoints Douglas S. Sommerville to Its Advisory Board

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Dec 18, 2023

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Jun 17, 2022

Independent Director recently sold CA$255k worth of stock

Recent updates

Therma Bright Inc. announced that it expects to receive CAD 3 million in funding

Therma Bright Inc. announced that it expects to receive CAD 0.4045 million in funding

Therma Bright Inc. Appoints Douglas S. Sommerville to Its Advisory Board

Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 3Q 2023)

Therma Bright Inc. announced that it has received CAD 1 million in funding

New major risk - Shareholder dilution

Therma Bright Inc. announced that it expects to receive CAD 1 million in funding

Second quarter 2024 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2023)

Insufficient new directors

Therma Bright Inc., Annual General Meeting, Dec 18, 2023

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2022)

Therma Bright Inc. and Inretio Inc. Announces Successful Completion of Good Laboratory Practice Study for Its Breakthrough Preva™? Mechanical Thrombectomy Device

Second quarter 2023 earnings released: CA$0.003 loss per share (vs CA$0.005 loss in 2Q 2022)

Full year 2022 earnings released: CA$0.026 loss per share (vs CA$0.043 loss in FY 2021)

Insufficient new directors

Is Therma Bright (CVE:THRM) In A Good Position To Invest In Growth?

Therma Bright Inc. Provides Update on FDA EUA Review Process

Therma Bright Inc. Provides Updates on Applications for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test

We Think Therma Bright (CVE:THRM) Can Afford To Drive Business Growth

Third quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.011 loss in 3Q 2021)

Therma Bright Submits Health Canada Application for Its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test for Point-of-Care (POC)

Therma Bright Inc. Provides Update on FDA EUA Application Process for Acuvid(TM) Covid-19 Rapid Antigen Saliva Test

Therma Bright to Submit Application to Health Canada for Approval of its AcuVid COVID-19 Rapid Antigen Saliva Test

Therma Bright Inc., Annual General Meeting, Jun 17, 2022

Second quarter 2022 earnings released: CA$0.005 loss per share (vs CA$0.008 loss in 2Q 2021)

Therma Bright Inc. announced that it has received CAD 6 million in funding

Therma Bright Inc. announced that it expects to receive CAD 6 million in funding

Therma Bright's AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration's Emergency Use Authorization Requirements

Therma Bright Inc. Completes U.S. Clinical Performance Study Subject Recruitment

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Therma Bright Inc. to Test AcuVidTM on the Highly Contagious COVID-19 Delta Variant; Completes Brazilian Clinical Study for Final FDA EUA Submission

Therma Bright Inc. Provides an Update on the Exceptional Performance of Its AcuVidTM COVID-19 Rapid Antigen Saliva Test's Brazilian Clinical Study

Therma Bright Inc. Provides Update on its Brazilian Clinical Study of its Innovative 15- Minute COVID-19 Antigen Saliva Test

Therma Bright Inc. Initiates Clinical Performance Study in Brazil for its AcuVid(TM) COVID-19 Rapid Saliva-Based Antigen Test

Therma Bright Inc. Submits Application to Research Ethics Board for Approval of Clinical Trials for AcuVid (TM) Covid-19 Rapid Saliva- Based Antigen Test

Therma Bright Enters into Clinical Trial Agreement for Its Acuvid(Tm) Covid-19 Rapid Saliva-Based Antigen Test

Independent Director recently sold CA$255k worth of stock

Therma Bright Inc. Reports Improved Accuracy for Covid-19 Rapid Saliva Antigen Test, CoviSafe, and Prepares for Prospective Studies

Therma Bright Inc. Appoints Ian Levine to the Advisory Board

New 90-day high: CA$0.35

First quarter 2021 earnings released: CA$0.018 loss per share

Chairman exercised options to buy CA$248k worth of stock.

New 90-day high: CA$0.28

Full year 2020 earnings released: CA$0.004 loss per share

Therma Bright Inc. (TSXV:THRM) completed the acquisition of assets of Saringer Life Science Technologies Inc. for CAD 0.43 million.

Therma Bright Inc. announced that it has received CAD 1.25 million in funding

New 90-day high - CA$0.30

Therma Bright Inc. announced that it expects to receive CAD 1 million in funding

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령